To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Prostate Cancer Clinical Trial

Official title:

A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05253053
• Other study ID #: TT00420CN04
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 13, 2022
• Est. completion date: December 2024

Study information

• Verified date: December 2023
• Source: TransThera Sciences (Nanjing), Inc.
• Contact: Caixia Sun, Ph.D.
• Phone: 025-58216298
• Email: clinicaltrial[@]transtherabio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and TNBC).

Description:

Study consists of three arms, Arm A is a Phase Ib/II study of TT-00420 tablet monotherapy, Arm B is a Phase Ib/II study of TT-00420 tablet in combination with atezolizumab (Tecentriq®), and Arm C is a Phase Ib/II study of TT-00420 tablet in combination with nab-paclitaxel (Abraxane®).

Arm A: TT-00420 Tablet Monotherapy Phase Ib will enroll patients with preferred indications including advanced cholangiocarcinoma, small cell lung cancer, HER2-negative breast cancer including TNBC, bladder cancer, prostate cancer, thyroid cancer, gastric cancer, gallbladder cancer and other advanced solid tumors to receive TT-00420 monotherapy. Phase Ib will be a dose escalation study of TT-00420 in combination, guided by 3+3 design, to determine a Recommended Phase 2 Dose (RP2D). Based on preliminary efficacy results, Phase II will enroll additional patients in select indications to evaluate the efficacy of TT-00420 monotherapy.

Arm B: TT-00420 tablet in combination with atezolizumab (Tecentriq®) Arm B will enroll patients with advanced biliary tract cancer. Phase Ib will be a dose escalation study of TT-00420 in combination with nab-paclitaxel, guided by 3+3 design, to determine a Recommended Phase 2 Dose (RP2D). Phase II will enroll additional patients with advanced biliary tract cancer to further evaluate the efficacy of the combination regimen.

Arm C: TT-00420 tablet in combination with nab-paclitaxel (Abraxane®) Arm C will enroll patients with advanced triple-negative breast cancer (TNBC). Phase Ib will be a dose escalation study of TT-00420 in combination with nab-paclitaxel, guided by 3+3 design, to determine a Recommended Phase 2 Dose (RP2D). Phase II will enroll additional patients with advanced TNBC to further evaluate the efficacy of the combination regimen.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 114
• Est. completion date: December 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. = 18 years of age

2. Arm A:Histopathological or cytologically documented locally advanced or metastatic and solid tumors(including but not limited to advanced cholangiocarcinoma, small cell lung cancer, HER2-negative breast cancer including TNBC, bladder cancer, prostate cancer, thyroid cancer, gastric cancer, gallbladder cancer and other advanced solid tumors.

Arm B:Histopathological or cytologically documented locally advanced or metastatic and Unresectable advanced biliary tract malignant tumors (except ampullary carcinoma).

Arm C:

• Histopathological invasive advanced TNBC with triple-negative receptor status that meets the institution standards was proved ER or PR by IHC (positive tumor nucleus<10% )

• HER2-negative (ASCO-CAP guideline [Wolff A C, 2018] )

3. Received all currently available standard treatments (unless the treatment is contraindicated, intolerable, or unavailable for any reason)

4. At least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors

5. Eastern Cooperative Oncology Group (ECOG) performance status = 2

6. 6. Adequate organ and bone marrow function(without receiving any hematopoietic growth factor, blood or platelet therapy within 1 week before the first dose.

• Complete blood count (CBC):

• Absolute Neutrophil Count (ANC)= 1.5 × 109/L

• Hemoglobin(Hgb)= 9 g/dl

• Platelets(Plt)= 75 × 109/L

• Liver function:

• AST/SGOT and ALT/SGPT = 2.5 x Upper Limit of Normal (ULN) or = 5.0 × ULN if liver metastases are present .

• Total bilirubin = 1.5 × ULN or direct bilirubin<ULN (if total bilirubin>1.5 ULN).

• Patients with hepatocellular carcinoma (HCC) and BTC: Child Pugh A or B (Score = 7).

• Renal fuction:

• serum creatinine = 1.5 × ULN or Calculated 24-hour clearance = 50 mL/min (Cockcroft Gault formula).

7. Must agree to take sufficient contraceptive methods to avoid pregnancy during the study and until at least 6 months after ceasing study treatment

8. Able to sign informed consent and comply with the protocol

Exclusion Criteria:

Patients who meet one or more of the following criteria will not be included in this study:

1. Women who are pregnant or lactating

2. Women of child-bearing potential (WOCBP) who do not use adequate birth control

3. Patients with any hematologic malignancy, including leukemia (any form), lymphoma, and multiple myeloma

4. Patients with a history of

• primary central nervous system tumors or

• carcinomatous meningitis (also known as leptomeningeal disease). Note: Patients with treated brain metastases that are off corticosteroids and have been clinically stable for 28 days are eligible for enrollment.

5. Impaired cardiac function or significant diseases, including but not limited to any of the following:

• left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)

• Congenital long QT syndrome

• QTcF = 450 msec on screening ECG

• Unstable angina pectoris = 3 months prior to starting study drug

• Acute myocardial infarction = 3 months prior to starting study drug

6. Patients who are currently receiving treatment with medication that has known risk to prolong the QT interval or induce Torsades de Pointes, and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug.

7. Patients with impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of TT-00420

8. Patients who have received chemotherapy, targeted therapy, or immunotherapy = 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy

9. Patients who have undergone major surgery or wide field radiotherapy = 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy

10. Patients who are currently receiving treatment with strong CYP3A inhibitors or inducers = 2 weeks prior to starting study drug.

11. Patients who have used of proton pump inhibitors (PPIs) within 4 days or histamine H2 blockers within 2 days prior to starting study drug

12. Human Immunodeficiency Virus (HIV) positive

13. Patients with active HBV infection (HBV DNA copy number = ULN) and/or HCV infection (HCV RNA copy number = ULN)

14. Patients with active tuberculosis

15. Has received a live-virus vaccination within 30 days of planned first dose Note:Seasonal flu and COVID-19 vaccines are permitted before enrollment at least 7 days.

16. Patients with a history of medical conditions, treatment, or abnormal laboratory tests that could affect the results of the study, interfere with study participation and compliance per investigator's judgment

17. ?Note?:The following three types of patients may be enrolled after being determined by the sponsor:

?Patients who have received emergency, low-dose, systemic immunosuppressive therapy (for example, one-time dexamethasone administration for vomiting);

? Patients who need steroid prophylaxis and have a history of intravenous contrast agent allergic reactions should use MRI for baseline and follow-up tumor assessment;

?The use of inhaled corticosteroids to treat chronic obstructive pulmonary disease, the use of mineralocorticoids (such as fludrocortisone) to treat patients with orthostatic hypotension and the use of low-dose supplementary corticosteroids to treat adrenal insufficiency are permitted.

Arm B: TT-00420 tablet in combination with Atezolizumab Injection (Tecentriq ®):

Subjects who meet one or more of the following criteria are also not allowed to participate in this study.

18. A history of severe allergies, immune stress, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.

19. Known to have hypersensitivity or allergies to any ingredient of Chinese hamster ovary cells or atelizumab injection.

20. History of autoimmune diseases, including but not limited to myasthenia gravis, autoimmune myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and antiphospholipid syndrome related Vascular thrombosis, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis or glomerulonephritis.

?Note?The following two types of patients may be enrolled after being determined by the sponsor: ? Patients who have a history of autoimmune hypothyroidism but have stable doses of thyroid replacement hormone therapy; ? Patients who use stable doses of insulin therapy to control type I diabetes may can be enrolled.

21. Patients who have a history of allogeneic stem cell or solid organ transplantation.

22. Patients who have a history of non-specific pulmonary fibrosis, tissue pneumonia (such as: bronchiolitis obliterans, unknown tissue pneumonia), drug-induced pneumonia, or active pneumonia showed by chest CT scan.

?Note?radiation pneumonitis (fibrosis) exist in the radiation area can be enrolled.

23. Patients who have received systemic immunostimulatory drugs therapy (including but not limited to interferon or IL-2) = the shorter one of 4 weeks or 5 half-lives of immunostimulatory drugs.

24. Patients who have received systemic corticosteroids or other systemic immunosuppressive drugs (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, and Tumor Necrosis Factor (TNF)) within 2 weeks prior to starting study.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Biliary Tract Cancer
• Biliary Tract Neoplasms
• Bladder Cancer
• Breast Neoplasms
• Cholangiocarcinoma
• Gallbladder Cancer
• Gallbladder Neoplasms
• Gastric Cancer
• HER2-negative Breast Cancer
• Prostate Cancer
• Small Cell Lung Carcinoma
• Small-cell Lung Cancer
• Thyroid Cancer
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• TT-00420
TT-00420 tablet will be administered orally once daily per protocol defined schedule.
• Combination Product: Atezolizumab
Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
• Combination Product: Nab-Paclitaxel
Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing
China	Peking University Third Hospital	Beijing
China	Jilin Cancer Hospital	Changchun	Jilin
China	Hunan Cancer Hospital	Changsha	Hunan
China	Shandong Cancer Hospital	Jinan	Shandong
China	Nanjing Drum Tower Hospital	Nanjing	Jiangsu
China	Fudan Univisity Shanghai Cancer Center	Shanghai
China	The First Affiliated Hospital of Wannan Medical College	Wuhu	Anhui
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
TransThera Sciences (Nanjing), Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Potential relationship between efficacy and biomarkers	Evaluation of biomarkers, including but not limited to, FGFR2 alterations, PD-L1 expression, dMMR, MSI, TNBC subtype and TMB	Through study completion, an average of 9 months
Other	changes of main circulating metabolites of TT-00420 in plasma		Through study completion, an average of 9 months
Primary	Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment	As assessed per NCI Common Toxicity Criteria for Adverse Events, version 5.0	Up to 30 days from the last dose
Primary	Dose limiting toxicity (DLT)	Dose escalation cohorts are monitored and assessed using the NCI Common Toxicity Criteria for Adverse Events, version 5.0.	Up to 21 days from the first dose
Secondary	Objective Response Rate (ORR)	The proportion of subjects who achieved a complete response (CR) or a partial response (PR) based on RECIST version 1.1.	Through study completion, an average of 9 months
Secondary	Disease Control Rate (DCR)	Defined as CR + PR + stable disease (SD) based on RECIST version 1.1.	Through study completion, an average of 9 months
Secondary	Duration of Objective Response (DOR)	Duration of response for CR or PR based on RECIST version 1.1.	Through study completion, an average of 9 months
Secondary	Progression Free Survival (PFS)		From first study drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary	Overall Survival (OS)		From first study drug administration until the date of death from any cause, assessed up to 24 months
Secondary	Area under the curve (AUC0-8)	Blood samples will be collected at designated time points for pharmacokinetic analysis of TT-00420	From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)
Secondary	Area under the curve (AUC0-t)	Blood samples will be collected at designated time points for pharmacokinetic analysis of TT-00420	From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)
Secondary	Maximum observed concentration (Cmax)	Blood samples will be collected at designated time points for pharmacokinetic	From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)
Secondary	Half-life (T1/2)		From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)
Secondary	Time to Maximum Concentration (Tmax)		From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)
Secondary	Volume of Distribution		From Cycle 1 Day 1 to Cycle 2 Day 1 (each cycle is 21 days)